epithelial ovarian cancer
Conditions
Interventions
Gold Standard:pathological examination
Index test:tumor associated antigens and autoantibodies
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.EOC group: a)Aged from 18 to 80 years; b)Clinical diagnosis was primary epithelial ovarian cancer; c)Surgery was performed to remove the primary tumor and metastasis, and adjuvant chemotherapy was performed after surgery; d)Signed informed consent. 2.Control Group1(benign ovarian diseases group): a)Aged from 18 to 80 years; b)Clinical diagnosis was benign ovarian diseases such as benign teratoma, ovarian endometriosis and ovarian serous cystic adenoma, etc; c)Signed informed consent. 3.Control Group2(autoimmune diseases group): a)Aged from 18 to 80 years; b)The sample was collected during the active stage of disease; c)Signed informed consent. 4.Control Group3(other gynaecological tumor group): a)Aged from 18 to 80 years; b)The clinical diagnosis was primary cervical, endometrial or vulvar cancer; c)Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.EOC group: a)Patients with recurrent epithelial ovarian cancer; b)Suffering from blood system disease or immune deficiency; c)Patients for whom samples were not available; d)Patients who refuse regular chemotherapy; e)Patients who are also participating in other clinical trials or clinical studies. 2.Control Group1(benign ovarian diseases group): a)The pathological diagnosis was malignant tumor; b)Suffering from blood system disease or immune deficiency; c)Patients for whom samples were not available; d)Patients who are also participating in other clinical trials or clinical studies. 3.Control Group2(autoimmune diseases group): a)Suffering or having suffered from malignant tumors; b)Suffering from blood system disease or immune deficiency; c)Patients for whom samples were not available; d)Patients who are also participating in other clinical trials or clinical studies. 4.Control Group3(other gynaecological tumor group): a)Suffering from blood system disease or immune deficiency; b)Patients for whom samples were not available; c)Patients who are also participating in other clinical trials or clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor associated antigens and autoantibodies; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical characteristics;Pathological examination;Accuracy;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactHaixia Li
Peking University First Hospital
Outcome results
None listed